CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada

CRISPR Therapeutics AG

2024-Q3 EPS reported -$3.92 revenue$1,623,000

Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.
CASGEVY approved for SCD and TDT in Switzerland and Canada; 45 ATCs activated globally.
Approximately 40 patients have had cell collections across all regions as of mid-October.
CTX112 Phase 1 data to be presented at ASH 2024: 67% ORR, 44% CRR in lymphoma patients.
R&D expenses $82.2M (down from $90.7M); collaboration expense net $11.2M (down from $23.4M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.